Nejvíce citovaný článek - PubMed ID 10340815
Endurance training increases the beta-adrenergic lipolytic response in subcutaneous adipose tissue in obese subjects
International journal of obesity and related metabolic disorders | Int J Obes Relat Metab Disord
Zdroj
AIMS/HYPOTHESIS: The aim of this study was to investigate whether dynamic strength training modifies the control of lipolysis, with particular attention paid to the involvement of the antilipolytic adrenergic alpha 2A receptor (ADRA2A) pathway. METHODS: Twelve obese men (age: 47.4+/-2.8 years; BMI: 32.7+/-0.9) were investigated during a 210-min euglycaemic-hyperinsulinaemic clamp conducted before and after 3 months of dynamic strength training. Before and during the third hour of the clamp, the lipolytic effect of a perfusion of isoproterenol or adrenaline (epinephrine) alone or associated with the ADRA2A antagonist phentolamine was evaluated using the microdialysis method of measuring extracellular glycerol concentration (EGC) in subcutaneous abdominal adipose tissue (SCAAT). In addition, biopsies of SCAAT were carried out before and after training to determine mRNA levels RESULTS: The training increased insulin sensitivity in adipose tissue. The decrease of EGC was more pronounced during the clamp conducted after the training period than during the clamp done in pre-training conditions. Before and after the training, catecholamines induced an increase in EGC, the increase being lower during the clamp on each occasion. The isoproterenol-induced increase in EGC was higher after the training. Adrenaline-induced lipolysis was potentiated by phentolamine after but not before the training. There were no training-induced changes in mRNA levels of key genes of the lipolytic pathway in SCAAT. CONCLUSIONS/INTERPRETATION: In obese subjects, dynamic strength training improves whole-body and adipose tissue insulin responsiveness. It increases responsiveness to the adrenergic beta receptor stimulation of lipolysis and to the antilipolytic action of catecholamines mediated by ADRA2As.
- MeSH
- adrenalin farmakologie MeSH
- agonisté beta-2-adrenergních receptorů MeSH
- alfa-2-adrenergní receptory - agonisté MeSH
- alfa-2-adrenergní receptory - antagonisté MeSH
- alfa-2-adrenergní receptory genetika metabolismus MeSH
- beta-2-adrenergní receptory genetika metabolismus MeSH
- cAMP-fosfodiesterasy genetika fyziologie MeSH
- cvičení fyziologie MeSH
- cyklické nukleotidfosfodiesterasy, typ 3 MeSH
- dospělí MeSH
- fentolamin farmakologie MeSH
- glycerol analýza krev MeSH
- glykemický clamp MeSH
- inzulin fyziologie MeSH
- inzulinová rezistence fyziologie MeSH
- isoprenalin farmakologie MeSH
- kyseliny mastné neesterifikované krev MeSH
- lidé středního věku MeSH
- lidé MeSH
- lipolýza MeSH
- messenger RNA analýza MeSH
- metabolismus lipidů MeSH
- obezita metabolismus patofyziologie MeSH
- podkožní břišní tuk chemie metabolismus MeSH
- sterolesterasa genetika fyziologie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- práce podpořená grantem MeSH
- Názvy látek
- adrenalin MeSH
- agonisté beta-2-adrenergních receptorů MeSH
- alfa-2-adrenergní receptory - agonisté MeSH
- alfa-2-adrenergní receptory - antagonisté MeSH
- alfa-2-adrenergní receptory MeSH
- beta-2-adrenergní receptory MeSH
- cAMP-fosfodiesterasy MeSH
- cyklické nukleotidfosfodiesterasy, typ 3 MeSH
- fentolamin MeSH
- glycerol MeSH
- inzulin MeSH
- isoprenalin MeSH
- kyseliny mastné neesterifikované MeSH
- messenger RNA MeSH
- sterolesterasa MeSH